Trial Profile
First-in-human Trial of the Coronavirus Virus-like Particle Subunit Vaccine ABNCoV2 in SARS-CoV-2-naïve Adult Volunteers in Good Health
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs ABNCoV2 cVLP based COVID 2019 vaccine AdaptVac (Primary) ; MF 59
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Acronyms COUGH-1
- 15 Mar 2022 Planned number of patients changed from 42 to 45.
- 15 Mar 2022 Status changed from active, no longer recruiting to completed.
- 18 Nov 2021 Status changed from recruiting to active, no longer recruiting.